Money, Money, Money
It is not just ABBA who sang about “Money”, there are opportunities to get support with development and funding by way of grants.
It is not just ABBA who sang about “Money”, there are opportunities to get support with development and funding by way of grants.
There is an old saying that “you cannot teach an old dog new tricks”. Our Director, James Hall challenges that and says it depends on how willing and open the old dog is to learn.
If you are tinkering under the bonnet and feel you require the diagnostics approach a specialist consultancy, such as JensonR+ can help. We aid in the strategy; the maintenance by fixing faults before they become running issues and can also give you a regulatory MOT.
Earth day may have past, but we should not lose sight of the need to protect and help the planet we all live on – our home. In the UK there is a Private Members Bill going through parliament - The Climate & Ecological Emergency Bill.
If you are a company or an individual wishing to promote a medicine by way of advertising, you need to ensure you know the rules of the road before you embark on this as there are many important factors to consider.
There are two words which often sit together when organisations discuss brand plans and company objectives for these, “Strategy and Tactics”. Have you however paused to consider them in full and to understand how they can guide you and what those differences are?
The page is still nearly blank for 2022 and now is the time if you’ve not already done so to sit back and reflect on what went well in 2021 and changes that need to be made for 2022. Are you going to repeat those “learnings” from 2021 or make a step change and see things possibly in a different light?
The EC Commission opened a consultation on the 31st August on Pharmacovigilance activities (Amendment Regulation (EU) 520/2012. This consultation closes on the 15th October at 12.00CET so there is not long to go to get your thoughts submitted back to them
Submission dates for 150-days assessment procedure for national marketing authorisation applications containing new active substances.
The MHRA has published its Delivery Plan for 2021-2023. Their focus is the platform of “putting patients first: A new era for our agency”. The goal of this plan is to help ensure meaningful outcomes for patients, protecting public health through excellence in regulation and becoming a truly world-leading regulator.